Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.66 | N/A | +0.03% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.66 | N/A | +0.03% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to patient care and shareholder value. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to patients and shareholders.
Amgen's slight EPS beat indicates solid performance in managing costs and profitability. The stock's 1.94% increase reflects investor confidence in the company's ability to deliver value, despite the lack of revenue data and future guidance. Investors may view the EPS beat as a positive sign for ongoing operations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
T-MOBILE US INC
Oct 28, 2019